No profile data available.
Oncotelic Therapeutics, Inc. (OTLC) is a healthcare company in the additional cancer treatment drugs industry, based in Agoura Hills, United States, with about 38 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of $249.28 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $9.15 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer.
Oncotelic Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$9.15 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Lisata Therapeutics, Inc. (LSTA), Phio Pharmaceuticals Corp. (PHIO), Bolt Biotherapeutics, Inc. (BOLT), Moleculin Biotech, Inc. (MBRX).